Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs) at its Visp (CH) site.
As demand for bio-technology surges, specialty chemical manufacturers are looking at business through a new lens to bring safe products to market more quickly. The New York Center for Innovation is capitalizing on this growing dynamic by providing a resourceful “plug and play” facility with existing turnkey infrastructure to promote business opportunity.
With great optimism surrounding two recent vaccines for COVID-19, there is renewed hope for 2021, particularly starting in the second quarter of the year. As such, the Society of Chemical Manufacturers & Affiliates (SOCMA) is rescheduling the Specialty & Custom Chemicals Show, originally set for February, to April 14-16, 2021, at the Omni in Fort Worth, TX.
SOCMA member Lonza congratulates Moderna on interim Phase 3 clinical trial data.
ChemDesign is pleased to announce the completion of its new technology center. This facility was developed and built by Keller Inc., with construction completed in the fall of 2020. The 25,000 sq. ft. facility houses multiple functional areas and will serve as the centerpiece and communication hub for the company.
SOCMA Vows to Work with New Administration to Advance Issues Important to Specialty Chemical Industry
The Society of Chemical Manufacturers & Affiliates (SOCMA) today pledged to work with the newly elected Presidential Administration and Congress to advance key issues vital to the success of its members and the specialty chemical industry.
Pierre-Alain Ruffieux today joins Lonza Group in the role of Chief Executive Officer. Albert Baehny has taken the role of CEO ad interim since November 2019. He will now work with Pierre-Alain to ensure a smooth handover of leadership before returning to his role as Chairman of the Board of Directors.
Lonza announced today that the company has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19.
Sun Chemical released its 11th annual Corporate Sustainability Report for the year ending 2019.
Pilot Chemical Corp., through its subsidiary Mason Chemical Company, has secured acceptance from the Environmental Protection Agency (EPA) to add a SARS-CoV-2 claim, along with four new antimicrobial claims, to the label of its Maguard® 5626 product.